-transparent.png){kind=logo}
We investigated the immunological heterogeneity of plasma Tg in thyroid cancer patients using monoclonal antibodies in an immunoradiometric assay and a conventional RIA system with a polyclonal rabbit antibody. The results were compared with measurements of plasma Tg in patients with nonmalignant disease. We can demonstrate an increased immunological heterogeneity in tumor patients compared with patients with non-malignant thyroid diseases. In one case the Tg value measured by a monoclonal test system exceeded the value obtained by a polyclonal RIA system in the same sample by a factor of 25. It has to be further investigated whether this increase in heterogeneity is of diagnostic value in the follow-up of thyroid cancer patients.
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
October 1986,
Annals of the Academy of Medicine, Singapore,
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
December 2008,
Best practice & research. Clinical endocrinology & metabolism,
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
April 2005,
Clinical chemistry,
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
August 1981,
Lancet (London, England),
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
January 1999,
Clinical oncology (Royal College of Radiologists (Great Britain)),
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
July 1984,
Blood,
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
September 2010,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
July 1973,
Acta endocrinologica,
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
February 1987,
Cancer,
B Heilig, and
M Hüfner, and
B Dörken, and
H Schmidt-Gayk
May 1986,
The Quarterly journal of medicine,
